Cargando…

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes

Purpose. To further validate the prognostic power of the biomarker PDE4D7, we investigated the correlation of PDE4D7 scores adjusted for presurgical clinical variables with longitudinal postsurgical biological outcomes. Methods. RNA was extracted from biopsy punches of resected tumors (550 patients;...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Strijp, Dianne, de Witz, Christiane, Vos, Pieter C., den Biezen-Timmermans, Eveline, van Brussel, Anne, Wrobel, Janneke, Baillie, George S., Tennstedt, Pierre, Schlomm, Thorsten, Heitkötter, Birthe, Huss, Sebastian, Bögemann, Martin, Houslay, Miles D., Bangma, Chris, Semjonow, Axel, Hoffmann, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083737/ https://www.ncbi.nlm.nih.gov/pubmed/30147955 http://dx.doi.org/10.1155/2018/5821616

Ejemplares similares

The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status
por: van Strijp, Dianne, et al.
Publicado: (2019)

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases
por: Böttcher, René, et al.
Publicado: (2016)

The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes
por: Gulliver, Chloe, et al.
Publicado: (2022)

Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies
por: Gulliver, Chloe, et al.
Publicado: (2023)

Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners
por: Houslay, Kirsty F., et al.
Publicado: (2017)

Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST
por: Heitkötter, Birthe, et al.
Publicado: (2016)

Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid
por: Heitkötter, Birthe, et al.
Publicado: (2018)

Retracted: Phosphorylation of PDE4A5 by MAPKAPK2 attenuates fibrin degradation via p75 signalling
por: Houslay, K F, et al.
Publicado: (2019)

Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
por: Cameron, Ryan T., et al.
Publicado: (2013)

Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains
por: Bolger, Graeme B., et al.
Publicado: (2015)

Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression
por: Böttcher, R, et al.
Publicado: (2015)

PDE4-Mediated cAMP Signalling
por: Fertig, Bracy A., et al.
Publicado: (2018)

Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5
por: Bolger, Graeme B, et al.
Publicado: (2002)

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases
por: Omar, Faisa, et al.
Publicado: (2019)

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells
por: Henderson, D J P, et al.
Publicado: (2014)

Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region
por: Gulliver, Chloe, et al.
Publicado: (2023)

Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model
por: Boomkamp, S D, et al.
Publicado: (2014)

Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011)

p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway
por: Sachs, Benjamin D., et al.
Publicado: (2007)

EGFR as a stable marker of prostate cancer dissemination to bones
por: Nastały, Paulina, et al.
Publicado: (2020)

Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer
por: Inda, Márcia A., et al.
Publicado: (2021)

Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)

Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches
por: Tibbo, Amy J., et al.
Publicado: (2019)

Prognostic impact of CD34 and SMA in cancer‐associated fibroblasts in stage I–III NSCLC
por: Schulze, Arik Bernard, et al.
Publicado: (2019)

Comparing instructional strategies to support student teachers’ learning to prepare an open-minded citizenship education lesson
por: van Brussel, Suzan, et al.
Publicado: (2023)

Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation
por: Vang, Amanda G., et al.
Publicado: (2016)

Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
por: Stock, Katharina, et al.
Publicado: (2017)

Geometric methods in PDE’s
por: Citti, Giovanna, et al.
Publicado: (2015)

Optimization with PDE constraints
por: Pinnau, Rene, et al.
Publicado: (2008)

PDE3 is the major cGMP-PDE in adult mouse ventricular cardiomyocytes
por: Götz, Konrad R, et al.
Publicado: (2013)

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
por: Kayık, Gülru, et al.
Publicado: (2017)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

Frontiers in PDE-constrained optimization
por: Antil, Harbir, et al.
Publicado: (2018)

Numerical PDE-constrained optimization
por: De los Reyes, Juan Carlos
Publicado: (2015)

Trends in PDE constrained optimization
por: Leugering, Günter, et al.
Publicado: (2014)

Pseudodifferential operators and nonlinear PDE
por: Taylor, Michael E
Publicado: (1991)

Control and optimization with PDE constraints
por: Bredies, Kristian, et al.
Publicado: (2013)

Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme
por: Tejeda, Gonzalo S., et al.
Publicado: (2020)

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
por: Coleman, D. Jackson, et al.
Publicado: (2020)

A Yeast-Based Chemical Screen Identifies a PDE Inhibitor That Elevates Steroidogenesis in Mouse Leydig Cells via PDE8 and PDE4 Inhibition
por: Demirbas, Didem, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0qbhnelg9ht33fhm67ga1bc8ff